Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe
Effects of natalizumab treatment on the CSF proteome of multiple sclerosis patients.
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis.
Study Suggests Targeting B Cells May Help with MS
Imaging Microglial/Macrophage Activation in Spinal Cords of Experimental Autoimmune Encephalomyelitis Rats by Positron Emission Tomography Using the Mitochondrial 18 kDa Translocator Protein Radioligand [18F]DPA-714.
Autoimmune myelopathies.
Central Nervous System Herpes Simplex and Varicella-Zoster Virus Infections in Natalizumab-Treated Patients.
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Chronic inflammatory demyelinating polyneuropathy following malignant melanoma.
The ketogenic diet as a treatment paradigm for diverse neurological disorders.
Detecting cortical lesions in multiple sclerosis at 7 T using white matter signal attenuation.
Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial.
Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf.
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
Acute disseminated encephalomyelitis--a prospective study of clinical profile and in-hospital outcome predictors.
The investigation of acute optic neuritis: a review and proposed protocol.
Natural History of Multiple Sclerosis Symptoms
Long-term effects of dalfampridine in patients with multiple sclerosis.
High-field imaging of neurodegenerative diseases.
Tysabri
Systematic approaches to central nervous system myelin.
Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis.
Pages
« first
‹ previous
…
148
149
150
151
152
153
154
155
156
…
next ›
last »